Mahsa Babaei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahsa Babaei has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Soheila Kashanian
Department of Applied Chemistry, Faculty of Chemistry, Razi University, Kermanshah, Iran; Nanobiotechnology Department, Faculty of Innovative Science and Technology, Razi University, Kermanshah, Iran
3 shared publications Sasan Abbasi Majd
Department of Applied Chemistry, Faculty of Chemistry Razi University Kermanshah Iran
2 shared publicationsZahra Shekarbeygi
Nano Drug Delivery Research Center, Health Technology Institute Kermanshah University of Medical Sciences Kermanshah Iran
2 shared publications- Helgi Birgir Schiöth
Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.
1 shared publication Mehran Miroliaei
1 shared publication- Mohamed H. Al-Sabri
Department of Pharmaceutical Bioscience, Uppsala University, 751 24 Uppsala, Sweden
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 204
Liposomal and liposome-based formulations of pentacyclic triterpenoids in cancer nanomedicine: A critical appraisal of preclinical progress and future perspectives
- 30 October 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 204
Open AccessLiposomal and liposome-based formulations of pentacyclic triterpenoids in cancer nanomedicine: A critical appraisal of preclinical progress and future perspectives
- 25 August 2024
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 72 (1) , 237-246
Alginate‐derived carbon dots for “turn off–on” anti‐neoplastic 5‐fluorouracil sensing in biological samples
As a chemotherapy drug, 5‐fluorouracil (5‐FU) has been used for colon cancer for decades. Excessive levels of 5‐FU in the human body can lead to notable adverse effects, including severe diarrhea, infection, mouth sores, skin peeling, skin inflammation, and ulcers, which are important and relatively common digestive side effects. In addition, 5‐FU is an analog of uracil and also has similarities to pyrimidines. Therefore, it is not easy to separate them. This research presented a sensor capable of detecting drugs in minimal amounts. An alginate‐derived carbon dot (CD) was synthesized by unique optical properties that obey an on–off fluorescence mechanism for 5‐FU sensing. Introducing copper (Cu(I)) to CDs results in fluorescence quenching through electron transfer. However, when 5‐FU is added to the system as an oxidizing agent, a redox reaction occurs on the surface of the CDs, which leads to the restoration of fluorescence as Cu(I) is altered to Cu(II). Experimental results showed a strong linear correlation (R2 = 0.99) in the concentration range of 1.00–45.00 nM, with the following linear regression, and revealed the relative standard deviation (RSD%) and detection limit of 2.57%, and 1.00 nM, respectively. These results validated the excellent detection capability of the proposed method even at low concentrations of 5‐FU and in the presence of other drugs and interfering substances. Also, the recovery of 5‐FU (varies from 100.46% to 113.7%, with RSD equal to 1.89–3.63) in serum samples indicates the absence of matrix interference in the determination of 5‐FU. In summary, this novel approach to developing a cost‐effective and sensitive sensor holds great potential for future applications in healthcare and related fields.
- 25 August 2024
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 72 (1) , 237-246
Alginate‐derived carbon dots for “turn off–on” anti‐neoplastic 5‐fluorouracil sensing in biological samples
As a chemotherapy drug, 5‐fluorouracil (5‐FU) has been used for colon cancer for decades. Excessive levels of 5‐FU in the human body can lead to notable adverse effects, including severe diarrhea, infection, mouth sores, skin peeling, skin inflammation, and ulcers, which are important and relatively common digestive side effects. In addition, 5‐FU is an analog of uracil and also has similarities to pyrimidines. Therefore, it is not easy to separate them. This research presented a sensor capable of detecting drugs in minimal amounts. An alginate‐derived carbon dot (CD) was synthesized by unique optical properties that obey an on–off fluorescence mechanism for 5‐FU sensing. Introducing copper (Cu(I)) to CDs results in fluorescence quenching through electron transfer. However, when 5‐FU is added to the system as an oxidizing agent, a redox reaction occurs on the surface of the CDs, which leads to the restoration of fluorescence as Cu(I) is altered to Cu(II). Experimental results showed a strong linear correlation (R2 = 0.99) in the concentration range of 1.00–45.00 nM, with the following linear regression, and revealed the relative standard deviation (RSD%) and detection limit of 2.57%, and 1.00 nM, respectively. These results validated the excellent detection capability of the proposed method even at low concentrations of 5‐FU and in the presence of other drugs and interfering substances. Also, the recovery of 5‐FU (varies from 100.46% to 113.7%, with RSD equal to 1.89–3.63) in serum samples indicates the absence of matrix interference in the determination of 5‐FU. In summary, this novel approach to developing a cost‐effective and sensitive sensor holds great potential for future applications in healthcare and related fields.
- 10 May 2024
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 71 (5) , 1032-1043
Simultaneous sensing of carbidopa and levodopa by a novel strategy based on dual‐emission ratiometric assay of modified carbon dots
Rapid control of the content of Parkinson's drugs in biological fluids and pharmaceutical formulations is of great importance because changes in the concentration of these drugs affect their bioavailability and biopharmaceutical properties. Therefore, we presented a simple and convenient method for the ratiometric detection of carbidopa and levodopa for carbon dots (CDs) dual‐fluorescent emission. Dual‐emission CDs were prepared from chitosan using a microwave method, following which the surface was chemically modified with terephthalaldehyde. CDs had two strong well‐separated peaks at 445 and 510 nm. The relative measurement of carbidopa and levodopa was based on the static extinction of CDs at 445 nm and increase at 510 nm, respectively. The linear range for carbidopa measurement was 2.5–300 nM, with a limit of detection (LOD) of 2.1 nM, and a relative standard deviation (RSD) of 1.68%. Further, the linear range for levodopa measurement was equal to 3.0–400 nM, with LOD and RSD% of 2.8 nM and 3.5%, respectively. Also, selectivity of ratiometric sensor in the presence of interferences was investigated, which showed that the recovery of carbidopa and levodopa in serum and urine samples has changed between 96.80% and 116.24% with RSD% 0.11–0.77. CDs also provided good results for the determination of carbidopa and levodopa in real samples, and had high selectivity in the presence of possible interferences.
- 10 May 2024
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 71 (5) , 1032-1043
Simultaneous sensing of carbidopa and levodopa by a novel strategy based on dual‐emission ratiometric assay of modified carbon dots
Rapid control of the content of Parkinson's drugs in biological fluids and pharmaceutical formulations is of great importance because changes in the concentration of these drugs affect their bioavailability and biopharmaceutical properties. Therefore, we presented a simple and convenient method for the ratiometric detection of carbidopa and levodopa for carbon dots (CDs) dual‐fluorescent emission. Dual‐emission CDs were prepared from chitosan using a microwave method, following which the surface was chemically modified with terephthalaldehyde. CDs had two strong well‐separated peaks at 445 and 510 nm. The relative measurement of carbidopa and levodopa was based on the static extinction of CDs at 445 nm and increase at 510 nm, respectively. The linear range for carbidopa measurement was 2.5–300 nM, with a limit of detection (LOD) of 2.1 nM, and a relative standard deviation (RSD) of 1.68%. Further, the linear range for levodopa measurement was equal to 3.0–400 nM, with LOD and RSD% of 2.8 nM and 3.5%, respectively. Also, selectivity of ratiometric sensor in the presence of interferences was investigated, which showed that the recovery of carbidopa and levodopa in serum and urine samples has changed between 96.80% and 116.24% with RSD% 0.11–0.77. CDs also provided good results for the determination of carbidopa and levodopa in real samples, and had high selectivity in the presence of possible interferences.
- Open Access
- 9 November 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (11) , 1136
The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro
There is no definite cure for Alzheimer’s disease (AD) due to its multifactorial origin. Drugs that inhibit acetylcholinesterase (AChE), such as rivastigmine, are promising symptomatic treatments for AD. Emerging evidence suggests that insulin therapy can hinder several aspects of AD pathology. Insulin has been shown to modify the activity of AChE, but it is still unknown how insulin and AChE interact. Combination therapy, which targets several features of the disease based on existing medications, can provide a worthy therapy option for AD management. However, to date, no studies have examined the potential interaction of insulin with AChE and/or rivastigmine in vitro. In the present study, we employed the Response Surface Methodology (RSM) as an in vitro assessment to investigate the effect of insulin on both AChE activity and rivastigmine inhibitory action using a common spectrophotometric assay for cholinesterase activity, Ellman’s method. Our results showed that insulin, even at high concentrations, has an insignificant effect on both the activity of AChE and rivastigmine’s inhibitory action. The variance of our data is near zero, which means that the dispersion is negligible. However, to improve our understanding of the possible interaction of insulin and rivastigmine, or its target AChE, more in silico modelling and in vivo studies are needed.
- 9 November 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (11) , 1136
Open AccessThe Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro
There is no definite cure for Alzheimer’s disease (AD) due to its multifactorial origin. Drugs that inhibit acetylcholinesterase (AChE), such as rivastigmine, are promising symptomatic treatments for AD. Emerging evidence suggests that insulin therapy can hinder several aspects of AD pathology. Insulin has been shown to modify the activity of AChE, but it is still unknown how insulin and AChE interact. Combination therapy, which targets several features of the disease based on existing medications, can provide a worthy therapy option for AD management. However, to date, no studies have examined the potential interaction of insulin with AChE and/or rivastigmine in vitro. In the present study, we employed the Response Surface Methodology (RSM) as an in vitro assessment to investigate the effect of insulin on both AChE activity and rivastigmine inhibitory action using a common spectrophotometric assay for cholinesterase activity, Ellman’s method. Our results showed that insulin, even at high concentrations, has an insignificant effect on both the activity of AChE and rivastigmine’s inhibitory action. The variance of our data is near zero, which means that the dispersion is negligible. However, to improve our understanding of the possible interaction of insulin and rivastigmine, or its target AChE, more in silico modelling and in vivo studies are needed.